8-K: ImmuCell Q3 Sales Decline 8% Amid Inventory Restocking

ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2025, showing an 8% decrease compared to the prior year, consistent with previous guidance regarding inventory restocking.

Summary

• Preliminary, unaudited total sales for the three-month period ended September 30, 2025, were $5.5 million, an 8% decrease ($505,000) compared to $6.0 million for the same period in 2024.
• Sales for the six-month period ended September 30, 2025, increased by 4% to $12.0 million, up from $11.5 million in 2024.
• Nine-month period sales ended September 30, 2025, rose by 7% to $20.0 million, compared to $18.7 million in 2024.
• Trailing twelve-month sales ended September 30, 2025, grew by 16% to $27.8 million, up from $23.8 million in 2024.
• The Q3 2025 sales drop is consistent with prior guidance from the Form 10-Q filing for Q2 2025, which warned of potential sales softening in the second half of 2025 due to customer and distributor inventory restocking after prolonged backlogs.
• Increased sales in the second half of 2024 and first half of 2025 were partly attributable to customers and distributors rebuilding First Defense inventories.
• A controlled study for Investigational Product use of Re-Tain, in collaboration with Michigan State University, has begun and is expected to continue through the end of 2025, utilizing available inventory and generating valuable data, though not expected to generate revenue or profit.
• The Non-Administrative New Animal Drug Application (NADA) for Re-Tain was submitted in early January 2025, with clearing inspectional observations at the contract manufacturer's facilities identified as the remaining hurdle for approval.

Sentiment

Score: 6

Explanation: While Q3 sales declined, this was an expected outcome due to inventory restocking dynamics. The company shows strong year-to-date and trailing twelve-month growth, active efforts to regain market share, and progress on new product development (Re-Tain study and NADA submission), despite a regulatory hurdle for NADA.

Positives

• Year-to-date sales for the nine-month period ended September 30, 2025, increased by 7% to $20.0 million.
• Trailing twelve-month sales ended September 30, 2025, showed significant growth of 16% to $27.8 million.
• The company is actively working to rebuild lost market share and is confident about developing sustainable, long-term growth for the First Defense product line.
• Initiated a controlled study for Re-Tain with Michigan State University, aiming to generate valuable data for a novel product to treat mastitis in dairy cows.

Negatives

• Preliminary Q3 2025 sales decreased by 8% to $5.5 million compared to Q3 2024.
• The drop in Q3 2025 sales indicates a softening trend in the second half of 2025, as previously warned.
• NADA approval for Re-Tain faces a remaining hurdle related to clearing inspectional observations at the contract manufacturer's facilities.

Risks

• Difficulties or delays in development, testing, regulatory approval, production, and marketing of products (including First Defense and Re-Tain).
• Competition within anticipated product markets.
• Customer acceptance of new and existing products.
• Product performance.
• Alignment between manufacturing resources and product demand, including consequences of backlogs.
• Uncertainty associated with the timing and volume of customer orders as the company comes out of a prolonged backlog.
• Adverse impacts of supply chain disruptions on operations and customer and supplier relationships.
• Commercial and operational risks relating to current and planned expansion of production capacity.

Future Outlook

The company expects to continue providing prompt, preliminary reports on product sales. It anticipates that the Re-Tain investigational product use study will continue through the end of 2025, generating valuable data. The company remains focused on and confident about developing sustainable, long-term growth of the First Defense product line and is aggressively working to rebuild lost market share. NADA approval for Re-Tain is pending the clearing of inspectional observations at the contract manufacturer's facilities.

Management Comments

• "Backlog depletion and buffer stock replenishment appear to have resulted in a one-time lift in sales volume during the first half of 2025."
• "Our sales team is aggressively working to rebuild lost market share now that we have the inventory levels needed to support continued growth going forward, and we remain focused on and confident about developing sustainable, long-term growth of the First Defense product line."

Industry Context

The animal health industry, particularly for dairy and beef cattle, often experiences fluctuations related to inventory management by distributors and producers. Companies in this sector continuously invest in R&D for novel treatments, such as those for mastitis, to address persistent health challenges and offer alternatives to traditional antibiotics, aligning with broader trends towards animal welfare and sustainable farming practices. Regulatory approvals, like NADA, are critical milestones for new product commercialization.

Stakeholder Impact

• Shareholders: Impacted by preliminary sales results, future growth prospects, and progress on new product development and regulatory approvals.
• Customers/Distributors: Benefit from improved inventory levels of First Defense, ensuring product availability.
• Employees: Sales team is actively working to rebuild market share, indicating ongoing operational efforts.
• Regulatory Authorities: Involved in the NADA approval process for Re-Tain, particularly regarding facility inspections.

Next Steps

• Host a conference call on November 14, 2025, at 9:00 AM ET to discuss the unaudited financial results for Q3 2025.
• Make an updated Corporate Presentation slide deck available after market closes on November 13, 2025.
• Continue the controlled study for Investigational Product use of Re-Tain with Michigan State University through the end of 2025.
• Work towards clearing inspectional observations at the contract manufacturer's facilities to achieve NADA approval for Re-Tain.

Key Dates

Recommendation

The Q3 sales decline, while expected, introduces near-term uncertainty. However, the company's year-to-date and trailing twelve-month sales growth, coupled with ongoing efforts to rebuild market share and advance the Re-Tain product (despite NADA approval delays), suggest a stable long-term outlook. The stock is likely to remain range-bound as investors weigh the expected sales softening against future growth initiatives and regulatory progress.

Keywords

ImmuCell, ICCC, animal health, dairy cattle, beef cattle, First Defense, Re-Tain, sales results, Q3 2025, preliminary sales, mastitis, NADA, SEC filing, 8-K